Pharmacotherapy for acute pancreatitis.
Our knowledge of acute pancreatitis is still far from complete and there is no unanimous agreement concerning the pathophysiological processes leading to typical alterations during the course of acute pancreatitis. We reviewed the paper published in the last decade on the pathophysiology and treatment of acute pancreatitis. It is difficult to translate the experimental therapeutic results into clinical practice. For example, lexipafant was efficacious in decreasing the severity and mortality of lethal pancreatitis in rats, but seems to have no effect on severe acute pancreatitis in humans. Thus, the main problem in acute pancreatitis, especially in the severe form of the disease, is the difficulty of designing clinical studies capable of giving reliable statistically significant answers regarding the benefits of the various proposed therapeutic agents previously tested in experimental settings. Thus, analgesia, supportive care, and treatment of the pulmonary and renal complications remain the cornerstones of the treatment of acute pancreatitis, especially in the severe form of the disease.
Pezzilli
Raffaele
R
Ospedale Sant'Orsola-Malpighi, Dipartimento di Medicina Interna e Gastroenterologia, Bologna, Italy. raffaele.pezzilli@aosp.bo.it
D000208:Acute Disease; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D010195:Pancreatitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D019283:Pancreatitis, Acute Necrotizing / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology